Related Experiment Video
Updated: Sep 29, 2025

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
miR-1251-5p Overexpression Inhibits Proliferation, Migration, and Immune Escape in Clear Cell Renal Cell Carcinoma by
Lin Yue1, Hualong Lin2, Shaofei Yuan2
1School of Nursing, Hunan University of Medicine, Huaihua 418000, China.
Background:
miR-1251-5p was identified as a tumor suppressor in a variety of malignancies; however, its biological function in clear cell renal cell carcinoma (ccRCC) is unknown.
Methods:
The Cancer Genome Atlas (TCGA) database was used to download expression information, including miR-1251-5p, in 521 ccRCC tissues and 71 ordinary tissues, and bioinformatics was used to explore possible target mRNAs. The relationship between miR-1251-5p, target mRNA activity, and clinical factors was examined. To estimate the biological activity of miR-1251-5p and target mRNA in ccRCC cells, we used MTT, colony formation, enzyme-linked immunosorbent, and Transwell assays. We employed a dual-luciferase reporter assay and a western blot to examine the molecular mechanisms of miR-1251-5p in ccRCC cells. In addition, the expressions of miR-1251-5p and target mRNA were further verified in the GEO database.
Results:
Our findings revealed that miR-1251-5p binds with NPTX2's 3'-UTR. In TCGA and GEO datasets, miR-1251-5p activity is found to be lower in ccRCC tissues than that in nearby conventional tissues, although NPTX2 activity is higher. In ccRCC sufferers, miR-1251-5p and NPTX2 act as biomarkers that indicate a bad prognosis. Meanwhile, in miR-1251-5p tissues, NPTX2 expression and multiple clinical variables (survival status, grade, T staging, N staging, M staging, and clinical stage) had significant differences (p < 0.05). Structurally, miR-1251-5p inhibited proliferation, migration, and immune escape of ccRCC cells by targeting NPTX2.
Conclusion:
Our findings indicate that miR-1251-5p constrained ccRCC cell advancement, migration, and immune evasion via targeting NPTX2, providing novel insights into ccRCC target treatment.
Insights
MicroRNA-1251-5p suppresses clear cell renal cell carcinoma (ccRCC) progression by targeting NPTX2. This finding offers new therapeutic strategies for ccRCC patients, highlighting miR-1251-5p as a potential biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNA-1251-5p is a known tumor suppressor in various cancers.
- Its specific role in clear cell renal cell carcinoma (ccRCC) remains unelucidated.
Purpose of the Study:
- To investigate the function and mechanism of miR-1251-5p in ccRCC.
- To explore miR-1251-5p as a potential therapeutic target and biomarker for ccRCC.
Main Methods:
- Utilized TCGA and GEO databases for expression analysis of miR-1251-5p and target genes in ccRCC tissues.
- Employed cell-based assays (MTT, colony formation, Transwell) and molecular techniques (dual-luciferase reporter, Western blot) to determine functional roles and mechanisms.
- Bioinformatic analysis identified potential target mRNAs.
Main Results:
- miR-1251-5p directly targets the 3'-UTR of NPTX2.
- Lower miR-1251-5p and higher NPTX2 expression were observed in ccRCC tissues compared to normal tissues.
- Both miR-1251-5p and NPTX2 serve as prognostic biomarkers for ccRCC patients.
- miR-1251-5p significantly inhibited ccRCC cell proliferation, migration, and immune escape by targeting NPTX2.
Conclusions:
- miR-1251-5p acts as a tumor suppressor in ccRCC by inhibiting cell proliferation, migration, and immune evasion through NPTX2.
- These findings provide novel insights into targeted therapy for ccRCC.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs

